Featured Research

from universities, journals, and other organizations

24-week Course Of Interferon-alpha Therapy Prolongs Survival In Patients Hepatitis C Virus

Date:
November 2, 2007
Source:
World Journal of Gastroenterology
Summary:
Scientists performed a matched historical controlled study on whether a 24-week course of interferon-alpha therapy, after curative treatment for primary hepatocellular carcinoma associated with hepatitis C virus, could influence tumor recurrence, patient survival, and liver function. Patients with sustained virological responses had reduced recurrence, prolonged survival and a preserved liver function. The group also determined that viral eradication was the most important factor in such patients.

Patients with the hepatitis C virus (HCV) have a risk of frequent recurrence and deterioration of liver function, even after curative treatment for the primary hepatocellular carcinoma (HCC). This unfavorable prognosis is associated with a sustained HCV infection. Thus, both the prevention of HCC recurrence and the preservation of liver function are high priorities when trying to improve the prognosis of patients with HCV-related HCC. Antiviral therapy for chronic hepatitis C (HCV) after treatment for primary HCC is the essential factor required for an improved prognosis.

Related Articles


A research article written by a study group at Japan's Hiroshima University Hospital, published on October 28 in the World Journal of Gastroenterology, suggests the importance of viral eradication. This study group performed a matched case-controlled study and compared 42 patients undergoing a 24-week course of interferon therapy and 42 patients who did not receive any interferon therapy. The purpose of the study was to determine whether a 24-week course of interferon-alpha therapy after curative treatment for HCV-associated HCC could possibly influence tumor recurrence, patient survival, and liver function.

The study group found that the second recurrence rate was significantly lower in patients that underwent interferon therapy as compared to those patients that did not have interferon therapy, although the first recurrence rate in patients with and without interferon therapy did not differ. Additionally, results also indicated that the interferon therapy patients had longer survival periods than the patients who did not have interferon therapy.

The study group also determined that when patients without interferon therapy were compared to patients without any virological response, only the virological responders within the interferon therapy group had a better prognosis with regard to the recurrence, liver function, and survival. Overall, the results indicated it is the sustained virological response that is the most important factor for decreasing the risk of HCC recurrence, including for the second recurrence and for prolonged survival. The state of the virological response improved the prognosis by suppressing the multicentric recurrence, which was related to the sustained hepatic necrosis and inflammation.

The study group also demonstrated that the state of the sustained virological response was responsible for preventing functional liver deterioration, which is related to the underlying HCV-related hepatic damage. Thus, patients with viral elimination are able to survive longer than both the patients without interferon therapy and the patients without virological response following interferon therapy, due to the decreased HCC recurrence and preservation of hepatic function.

After curative treatment of primary HCC, a 24-week course of interferon therapy should be recommended for the purpose of viral eradication.

Reference: Jeong SC, Aikata H, Katamura Y, Azakami T, Kawaoka T, Saneto H, Uka K, Mori N, Takaki S, Kodama H, Waki K, Imamura M, Shirakawa H, Kawakami Y, Takahashi S, Chayama K.Effects of a 24-week course of interferon-alpha therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma. World J Gastroenterol 2007; 13(40): 5343-5350


Story Source:

The above story is based on materials provided by World Journal of Gastroenterology. Note: Materials may be edited for content and length.


Cite This Page:

World Journal of Gastroenterology. "24-week Course Of Interferon-alpha Therapy Prolongs Survival In Patients Hepatitis C Virus." ScienceDaily. ScienceDaily, 2 November 2007. <www.sciencedaily.com/releases/2007/11/071102112038.htm>.
World Journal of Gastroenterology. (2007, November 2). 24-week Course Of Interferon-alpha Therapy Prolongs Survival In Patients Hepatitis C Virus. ScienceDaily. Retrieved January 24, 2015 from www.sciencedaily.com/releases/2007/11/071102112038.htm
World Journal of Gastroenterology. "24-week Course Of Interferon-alpha Therapy Prolongs Survival In Patients Hepatitis C Virus." ScienceDaily. www.sciencedaily.com/releases/2007/11/071102112038.htm (accessed January 24, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Saturday, January 24, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Disneyland Measles Outbreak Spreads To 5 States

Disneyland Measles Outbreak Spreads To 5 States

Newsy (Jan. 24, 2015) Much of the Disneyland measles outbreak is being blamed on the anti-vaccination movement. The CDC encourages just about everyone get immunized. Video provided by Newsy
Powered by NewsLook.com
Growing Measles Outbreak Worries Calif. Parents

Growing Measles Outbreak Worries Calif. Parents

AP (Jan. 23, 2015) Public health officials are rushing to contain a measles outbreak that has sickened 70 people across 6 states and Mexico. The AP&apos;s Raquel Maria Dillon has more. (Jan. 23) Video provided by AP
Powered by NewsLook.com
Smart Wristband to Shock Away Bad Habits

Smart Wristband to Shock Away Bad Habits

Reuters - Innovations Video Online (Jan. 23, 2015) A Boston start-up is developing a wristband they say will help users break bad habits by jolting them with an electric shock. Ben Gruber reports. Video provided by Reuters
Powered by NewsLook.com
This Is What It's Like To Date A Med Student

This Is What It's Like To Date A Med Student

BuzzFeed (Jan. 23, 2015) Dating is now speed-dating... or studying. Video provided by BuzzFeed
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins